

CAVERNOMAS CEREBRAIS EPILEPSIA

SONIZA VIEIRA ALVES-LEON Professora Titular de Neurologia da Universidade Federal do Estado do Rio de Janeiro Pesquisadora CNPq Cientista do Nosso Estado FAPERJ sonizavieiraalvesleon@gmail.com





Programa de Epilepsias da Universidade Federal do Rio de Janeiro – HUCFF\UFRJ

Laboratório de Neurociências Translacional da Universidade Federal do Estado do Rio de Janeiro -UNIRO

LabNet





CAVERNOMAS RELACIONADOS COM EPILEPSIA EPIDEMIOLOGIA DENTRO DO CONTEXTO DAS EPILEPSIAS

2009)

- A 70%) (Awad & Jabbour, 2006)
- European Epilepsy Brain Bank (Blumcke, 2015).
- 40% PODEM EVOLUIR COM EPILEPSIA FÁRMACO RESISTENTE **

** Ferrier CH, Aronica e, Leijten FS, Spliet wG, Boer K, van Rijen PC, van Huffelen AC (2007) electrocorticography discharge patterns in patients with a cavernous hemangioma and pharma- coresistent epilepsy. J Neurosurg 107:495–503. doi:10.3171/ JNS-07/09/0495

* 10–15 % DE TODAS AS MALFORMAÇÕES VASCULARES DO ENCÉFALO (Batra et al.,

• EPILEPSIA É A MANIFESTAÇÃO MAIS COMUM NOS CAVERNOMAS CEREBRAIS (40%

* JUNTO COM OUTRAS MALFORMAÇÕES VASCULARES CCMs respondem por 5.6 % **DE TODOS OS CASOS DE EPILEPSIAS ASSOCIADOS A PATOLOGIAS** segundo o



TERMINOLOGIA ILAE CAVERNOMAS RELACIONADO A EPILEPSIAS (CRE)

SPECIAL REPORT

Cavernoma-related epilepsy: Review and recommendations for management — Report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies

*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶Americo C. Sakamoto, ###Ulrich Sure, ****Matthew C. Walker and *††††*Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE

Epppping, 54 (12):2025-2035, 2018 00, 701 11 (1ep) 1202 **CAVERNOMA RELACIONADA A EPILEPSIA** DEFINIDO

CAVERNOMA NÃO RELACIONADO COM EPILEPSIA


CAVERNOMA RELACIONADA A EPILEPSIA PROVAVEL



ILAE classification of the epilepsies: Position paper of the **ILAE Commission for Classification and Terminology**

^{1,2,3}Ingrid E. Scheffer, ¹Samuel Berkovic, ⁴Giuseppe Capovilla, ⁵Mary B. Connolly,
⁶Jacqueline French, ⁷Laura Guilhoto, ^{8,9}Edouard Hirsch, ¹⁰Satish Jain, ¹¹Gary W. Mathern,
¹²Solomon L. Moshé, ¹³Douglas R. Nordli, ¹⁴Emilio Perucca, ¹⁵Torbjörn Tomson,
¹⁶Samuel Wiebe, ¹⁷Yue-Hua Zhang, and ^{18,19}Sameer M. Zuberi

Epilepsia, **(*):1-10, 2017 doi: 10.1111/epi.13709






*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶Americo C. Sakamoto, ###Ulrich Sure, ****Matthew C. Walker and ††††Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE

> *Epilepsia*, 54(12):2025–2035, 2013 doi: 10.1111/epi.12402


FENOMENOLOGIA ICTAL DA EPILEPSIA DO LOBO TEMPORAL





CCM TEMPORAL A ESQUERDA


CAVERNOMA RELACIONADA A EPILEPSIA DEFINIDO

100 m				
	view N			
File	View	Edit	Tool	
Sens TC				
10 uV 🛛 🔻				
<u> </u>	刺長		11	
1	www	~~~	rm	
2	F3-C3			
_				
3	C3-P3			
	P3-01			
4				
5	Fp2-F4	m	in	
	F4-C4			
6				
7	C4-P4		++	
	P4-02			
8			\sim	
9	FZ-CZ		~	
10				
11	-1 +77	ma	har	
	F7-T3			
12	F7-13	\sim	m	
13	T3-T5		-	
	T5-01			
14	m	tut		
15	Fp2-F8			
10	F8-T4			
16	-14	no	m	
17	T4-T6			
17	T6-02		T	
18			m	
M		1 1		
14	:32			
			-	
	1)	e	65	










*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶Americo C. Sakamoto, ###Ulrich Sure, *****Matthew C. Walker and ††††Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE

> *Epilepsia*, 54(12):2025–2035, 2013 doi: 10.1111/epi.12402

EPILEPSIA FOCAL + CCM

- CRISE NO MESMO **HEMISFÉRIO DO CCM MAS NÃO NA ZII** EXATA - NENHUMA OUTRA CAUSA PARA EPILEPSIA



CAVERNOMA RELACIONADA A EPILEPSIA PROVÁVEL

man war and a second and the second and a second water and a second a unger A. Manune Marken Ma March million manus and a second when the second of the second and the second of the second mon man man man man provide man and man and man and the second se whom who have a server and the serve Immy my man Man man man mm mound from May May may my for way and many and and and and and and and ساه متصفيه ملاحكم مصاد المصف بمناه بالأم الانتقاب المقام الانتقاب المصف مصاد مصاد مصاد مصاد مصاد الم






*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶Americo C. Sakamoto, ###Ulrich Sure, *****Matthew C. Walker and ††††Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE

> Epilepsia, 54(12):2025-2035, 2013 doi: 10.1111/epi.12402






19 anos Em 2011, aos 14 anos, apresentou crise tônico-clônica-generalizada

RM - CCM único, operada oxcarbazepina, 300 mg 2 x dia **Crise Ausência e POCS**

Vídeo-EEG - paroxismos de OL e OA e de PO generalizada

CAVERNOMA NÃO RELACIONADA A EPILEPSIA






LOCALIZAÇÃO CAVERNOMAS CEREBRAIS E EPILEPSIAS

*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶¶Americo C. Sakamoto, ###Ulrich Sure, ****Matthew C. Walker and ††††Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE *Enilensia* 54(12):2025-2035 2013

<i>Epilepsia</i> doi:
Table I. The anato
Localization
Frontal lobe Parietal lobe Temporal lobe
Occipital lobe Multilobar
Total lobar
Basal ganglia/thalamus
Supratentorial not specified
Total supratentorial
Brainstem Cerebellum
Infratentorial not specified
Total infratentorial
Orbital
Spinal cord
Other ^b
Total
^a Includes medulla oblongata, gland, third ventricle, and fourth ^b Corpus callosum, extradural et al. (1999).

a, 54(12):2025–2035, 2013 i: 10.1111/epi.12402



FATORES DE RISCO PARA EPILEPSIA RELACIONADA COM CAVERNOMA



LOCALIZAÇÃO SUPRATENTORIAL versus INFRATENTORIAL

CORTICAL versus SUBCORTICAL NOS CCMs SUPRATENTORIAIS

MESIOTEMPORAL versus NEOCORTICAL

SPECIAL REPORT

Cavernoma-related epilepsy: Review and recommendations for management — Report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies

*Felix Rosenow, †Mario A. Alonso-Vanegas, ‡Christoph Baumgartner, §Ingmar Blümcke, ¶Maria Carreño, #Elke R. Gizewski, **Hajo M. Hamer, *Susanne Knake, ††Philippe Kahane, ‡‡Hans O. Lüders, §§Gary W. Mathern, *Katja Menzler, ¶¶Jonathan Miller, ##Taisuke Otsuki, ***Cigdem Özkara, †††‡‡‡Asla Pitkänen, §§§Steven N. Roper, ¶¶Americo C. Sakamoto, ###Ulrich Sure, ****Matthew C. Walker and ††††Bernhard J. Steinhoff for the Surgical Task Force, Commission on Therapeutic Strategies of the ILAE

> *Epilepsia*, 54(12):2025–2035, 2013 doi: 10.1111/epi.12402

CONTROVERSUS

LOCALIZAÇÃO LOBAR

NÚMERO DE CAVERNOMAS

TAMANHO DA LESÃO E DEPÓSITO DE HEMOSIDERINA

FULL-LENGTH ORIGINAL RESEARCH

Surgical management and long-term seizure outcome epilepsy surgery for different types of epilepsy associ with cerebral cavernous malformations


*Christian von der Brelie, †Michael P. Malter, ‡Pitt Niehusmann, †Christian E. Elger, *Marec von Lehe, and *Johannes Schramm

*Departments of Neurosurgery, †Epileptology, and ‡Neuropathology, University of Bonn Medical Centre, Bonn, Germany

Table 2. Epilepsy/seizure semiology				
	DRE (%)	Chronic epilepsy (%)	Sp sei	
Complex partial seizures	66/76 (87)	7/20 (35)	(
Other focal seizures	10/76 (13)	10/20 (45)		
Generalized convulsions	59/76 (78)	10/20 (45)		
Secondary generalizing convulsions	52/59 (88)	5/10 (50)		
Mesial temporal sclerosis	6/76 (8)	I/20 (5)	(
Other pathologies (tumor, vascular, TBI)	6/76(8)	4/20 (18)	(

TBI, traumatic brain injury.


e	after
a	ted



DISTRIBUIÇÃO CCM em diferentes tipos de Epilepsias

Localização TEMPORAL > frequente EFR (p<0.05)

Localização áreas eloquentes > frequente nas Epilepsias Crônicas







MECANISMOS DE EPILEPTOGÊNESE CAVERNOMAS CEREBRAIS E EPILEPSIAS

(1) EPILEPTOGÊNESE DO TECIDO AO REDOR (2) EPILEPTOGENESE DO TECIDO REMOTO

Andre Palmini · Usha Aryal · Roland Coras · Eliseu Paglioli , Acta Neuropathol (2014) 128:55–65 DOI 10.1007/s00401-014-1294-y



- ***** Micro hemorragias Gliose Hemossideriana \star \star
- Displasias Focais Astrogliose BHE/Astrócitos
- ***** Clustter de citocinas pró-inflamatórias



Acta Neuropathol (2014) 128:55–65


CAVERNOMAS CEREBRAIS E EPILEPSIA MECANISMOS DE EPILEPTOGÊNESE Ao redor do CCM...


isquemia hipertensão venosa gliose/ resposta inflamatória alterações das camadas corticais como o que ocorre nas


Physiology of Human Cortical Neurons Adjacent to Cavernous Malformations and Tumors

CAVERNOMAS CEREBRAIS E EPILEPSIA MECANISMOS DE EPILEPTOGÊNESE


*Anne Williamson, †Peter R. Patrylo, *Sunghoon Lee, and *Dennis D. Spencer







(1) epileptogenesis do tecido cerebral ao redor do CCM (5x mais complexos com potenciais pos sinápticos excitatórios espontâneos, em 71% células)







journal homepage: www.elsevier.com/locate/epilepsyres

Beyond the lesion: The epileptogenic networks around cavernous angiomas


Amandine Sevy^a, Martine Gavaret^{a,b,c}, Agnès Trebuchon^{a,b,c}, Lisa Vaugier^{a,b,c}, Fabrice Wendling^e, Romain Carron^d, Jean Regis^d, Patrick Chauvel^{a,b,c}, Aileen Mc Gonigal^{a,b,c}, Fabrice Bartolomei^{a,b,c,*}




P4





P2





P5





-

.

. .

- - - - -




P3


P6




a)




b)



SEEG mostrando a hiperexcitabilidade neuronal no tecido subjacente ao CCM






CAVERNOMAS CEREBRAIS E EPILEPSIA MECANISMOS DE EPILEPTOGÊNESE Epileptogenese secundária - PATOLOGIA DUAL/TRÍPLICE


Acta Neuropathol (2014) 128:55–65 DOI 10.1007/s00401-014-1294-y

REVIEW

Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles

Lara E. Jehi · Andre Palmini · Usha Aryal · Roland Coras · Eliseu Paglioli





Ressecção completa mostrando o tecido adjacentemente anormal pode incluir displasia focal ESCLEROSE HIPOCAMPAL

CAVERNOMAS CEREBRAIS E EPILEPSIA MECANISMOS DE EPILEPTOGÊNESE Múltiplos Fatores

GENOTIPO CCM E GENES CANDIDATOS Brain Vascular Malformation Consortium (BVMC)

. 190 Hispanicos genotipados .817.810 SNPs

. 56 Genes candidatos:

. Vias inflamação/resposta imune

. Malformações vasculares

. Inflamação ou resposta imune (T, B, monócitos e macrófagos) . 830 SNPs analisados para associação com marcadores de gravidade da doença por CCM1





Nerissa U. Ko, MD, MAS, AAN, 2019







Blood-Brain Barrier Dysfunction, TGFβ Signaling, and Astrocyte Dysfunction in Epilepsy

UWE HEINEMANN,¹ DANIELA KAUFER,² AND ALON FRIEDMAN^{3*}

Epilepsia, 52(Suppl. 3):33-39, 2011 doi: 10.1111/j.1528-1167.2011.03034.x

IMMUNITY AND INFLAMMATION IN EPILEPSY

Molecular cascades that mediate the influence of inflammation on epilepsy

*Alon Friedman and †Ray Dingledine

*Department of Physiology and Neurobiology, Faculty of Health Sciences, Zlotowski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva, Israel; and †Department of Pharmacology, Emory Chemical

> Epilepsia, 49(Suppl. 2):24-32, 2008 doi: 10.1111/j.1528-1167.2008.01490.x

SUPPLEMENT - EARLY GLIAL DYSFUNCTION

Glia as a source of cytokines: Implications for neuronal excitability and survival

*Annamaria Vezzani, *Teresa Ravizza, *Silvia Balosso, and †Eleonora Aronica

IMMUNITY AND INFLAMMATION IN EPILEPSY (IIE2016)

Neuroinflammatory targets and treatments for epilepsy validated in experimental models

^{1,2,3}Eleonora Aronica, ^{4,5}Sebastian Bauer, ^{6,7}Yuri Bozzi, ⁶Matteo Caleo, ⁸Raymond Dingledine, ²Jan A. Gorter, ⁹David C. Henshall, ¹⁰Daniela Kaufer, ¹¹Sookyong Koh, ¹²Wolfgang Löscher, ^{13,14}Jean-Pierre Louboutin, ^{15,16}Michele Mishto, ^{4,17}Braxton A. Norwood, ¹⁸Eleonora Palma, ¹⁹Michael O. Poulter, ²⁰Gaetano Terrone, ²⁰Annamaria Vezzani, and ²¹Rafal M. Kaminski doi: 10.1111/j.1528-1167.2012.03540.x

FULL-LENGTH ORIGINAL RESEARCH

Interleukin-I β and microRNA-I46a in an immature rat model and children with mesial temporal lobe epilepsy


*Ahmed Omran, *Jing Peng, *Ciliu Zhang, *Qiu-Lian Xiang, †Jinfeng Xue, *Na Gan, *Huimin Kong, and *Fei Yin

1.1	11	,	

Brain inflammation initiates seizures

Jonathan K Kleen & Gregory L Holmes

opening a new realm of therapeutics (pages 1377–1383).



Biomarkers of cavernous angioma with symptomatic hemorrhage

Seán B. Lyne,¹ Romuald Girard,¹ Janne Koskimäki,¹ Hussein A. Zeineddine,¹ Dongdong Zhang,¹ Ying Cao,¹ Yan Li,² Agnieszka Stadnik,¹ Thomas Moore,¹ Rhonda Lightle,¹ Changbin Shi,¹ Robert Shenkar,¹ Julián Carrión-Penagos,¹ Sean P. Polster,¹ Sharbel Romanos,¹ Amy Akers,³ Miguel Lopez-Ramirez,⁴ Kevin J. Whitehead,⁵ Mark L. Kahn,⁶ Mark H. Ginsberg,⁴ Douglas A. Marchuk,⁷ and Issam A. Awad¹

O DESFECHO DOS ESTUDOS DE BIOMARCADORES FORAM PARA CASH **BIOMARCADORES IMUNOLÓGICOS SEMELHANTES EM EPILEPSIAS RESULTS. T**

(sCD14), VEGF, C-reactive protein (CRP), and IL-10 distinguishing CASH patients with 76% sensitivity and 80% specificity (P = 0.0003). The prognostic CASH biomarker (sCD14, VEGF, IL-1 β , and sROBO-4) was confirmed to predict a bleed in the subsequent year with 83% sensitivity and 93% specificity (*P* = 0.001). Genes associated with diagnostic and prognostic CASH biomarkers were differentially expressed in CASH lesional NVUs. Thirteen plasma miRNAs were differentially expressed between CASH and non-CASH patients.

CONCLUSION. Shared and unique biomarkers of recent symptomatic hemorrhage and of future bleeding in CA are mechanistically linked to lesional transcriptome and miRNA. The biomarkers may be applied for risk stratification in clinical trials and developed as a tool in clinical practice.

DIAGNÓSTICO sCD14, VEGF, PCR, IL-10

SENSIBILIDADE 76% ESPECIFICIDADE 80%


PROGNÓSTICO sCD14, VEGF, IL1-BETA, sROBO-4

SENSIBILIDADE 83% ESPECIFICIDADE 93%

Plasma Biomarkers of Inflammation and Angiogenesis Predict Cerebral Cavernous Malformation Symptomatic Hemorrhage or Lesional Growth

Short Communication

Romuald Girard,* Hussein A. Zeineddine,* Janne Koskimäki, Maged D. Fam, Ying Cao, Changbin Shi, Thomas Moore, Rhonda Lightle, Agnieszka Stadnik, Kiranj Chaudagar, Sean Polster, Robert Shenkar, Ryan Duggan, David Leclerc, Kevin J. Whitehead, Dean Y. Li, Issam A. Awad








Mesial temporal lobe epilepsy with hippocampal sclerosis (TLE-HS) is a frequent condition within the pharmacoresistant group of epilepsies classified as a syndrome with clinical, electroencephalographic, genetic and immunological features (Berg, 2009; Vezzani et al., 2011).

The release of inflammatory cytokines in mesial structures may activate mechanisms associated with prolonged epileptic seizure and neuronal damage (Balosso et al., 2009), and also neurogenesis, neuroplasticity and synaptic reorganization (Jankowsky and Patterson, 2001; Vezzani et al., 2011).

response to neuronal activity. NATURE REVIEWS | **NEUROSCIENCE Volume 14, January 2014**




Dimitris N. Xanthos and Jürgen Sandkühler, Neurogenic neuroinflammation: inflammatory CNS reactions in










Resection of the epileptogenic lesion abolishes seizures and reduces inflammatory cytokines of patients with temporal lobe epilepsy

Thereza Quirico-Santos ^{a,*}, Isabella D'Andrea Meira ^{a, b}, Aline C. Gomes ^a, Valeria C. Pereira ^b, Moises Pinto ^b, Marisa Monteiro^b, Jorge M. Souza^c, Soniza V. Alves-Leon^b


^a Department of Cellular and Molecular Biology, Institute of Biology, Fluminense Federal University, Rio de Janeiro Federal University, Rio de Janeiro, Brazil ^b Department of Neurology, Rio de Janeiro Federal University, Rio de Janeiro, Brazil ^c Department of Neurosurgery, Rio de Janeiro Federal University, Rio de Janeiro, Brazil




Contents lists available at SciVerse ScienceDirect


Journal of Neuroimmunology

journal homepage: www.elsevier.com/locate/jneuroim






÷		
l		
l		
l		
l		
l		
l		
l		
l		
L		




T. Quirico-Santos et al. / Journal of Neuroimmunology xxx (2012) xxx-xxx




Dimitris N. Xanthos and Jürgen Sandkühler, Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. NATURE REVIEWS | NEUROSCIENCE Volume 14, January 2014

Role of the gut microbiota in immunity and inflammatory disease

Nobuhiko Kamada¹, Sang-Uk Seo¹, Grace Y. Chen² and Gabriel Núñez¹





World Journal of Gastroenterology

Submit a Manuscript: http://www.f6publishing.com

World J Gastroenterol 2017 September 7; 23(33): 6164-6171

DOI: 10.3748/wjg.v23.i33.6164

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

ORIGINAL ARTICLE

Retrospective Study

Ketogenic diet poses a significant effect on imbalanced gut microbiota in infants with refractory epilepsy

Gan Xie, Qian Zhou, Chuang-Zhao Qiu, Wen-Kui Dai, He-Ping Wang, Yin-Hu Li, Jian-Xiang Liao, Xin-Guo Lu, Su-Fang Lin, Jing-Hua Ye, Zhuo-Ya Ma, Wen-Jian Wang

MANEJO COM DAE VERSUS CIRURGIA CAVERNOMAS CEREBRAIS E EPILEPSIAS

Contents lists available at ScienceDirect

Seizure

journal homepage: www.elsevier.com/locate/yseiz

Clinical outcome following medical treatment of cavernous malformation related epilepsy

Yoonju Lee^a, Kyoo Ho Cho^a, Hye Ihn Kim^a, Seung-Koo Lee^b, Yang-Je Cho^a, Kyoung Heo^a, Byung In Lee^{c,*}


- ► O controle das crises em 1 ano, com DAE, em pacientes com CCM/CRE (64,7%) foi semelhante aos de pacientes com Epilepsia recém diagnosticadas
- Falha após 2 DAE investigar possível indicaç de tratamento cirúrgico
- CRE TEMPORAL- falha na 1a. DAE considera cirurgia - fator preditivo de maior risco de falha (p=0.01)





CAVERNOMAS CEREBRAIS E EPILEPSIA **DROGAS ANTI EPILÉPTICAS** (DAE)








FULL-LENGTH ORIGINAL RESEARCH

The role of underlying structural cause for epilepsy classification: Clinical features and prognosis in mesial temporal lobe epilepsy caused by hippocampal sclerosis versus cavernoma

*Katja Menzler, *Patricia Thiel, *Anke Hermsen, †Xu Chen, ‡Ludwig Benes, ‡§Dorothea Miller, +SI Ilrich Sura *Susanna Knaka and *Falix Rosanow



Covariates are age at surgery, age at onset of epilepsy, and time interval between onset of epilepsy and operation for the two patient groups.

MTLE-CCM apresentam melhor controle das crises - Comissão da ILAE deve dar ênfase nas causas em futuras classificações

Significance: The results suggest that patients with MTLE-C show a more favorable postoperative outcome, supporting the commission's suggestion to put more emphasis on the underlying cause in future epilepsy classifications.



REVIEW


Cerebral cavernous malformations in the setting of focal epilepsies: pathological findings, clinical characteristics, and surgical treatment principles

Lara E. Jehi · Andre Palmini · Usha Aryal · **Roland Coras · Eliseu Paglioli**



Ethan A. Winkler¹, Caleb Rutledge¹, Mariann Ward², Tarik Tihan³, Patricia K. Sneed⁴, Nicholas Barbaro⁵, Paul Garcia⁶, Michael McDermott¹, Edward F. Chang²

CAVERNOMAS CEREBRAIS E EPILEPSIA ALGORÍTIMO PROPOSTO PARA MAIOR CONTROLE DA EPILEPSIA





DEPÓSITO DE HEMOSSIDERINA É MAIS UM INDICADOR DO DANO OCORRIDO DO QUE UM FATOR CAUSAL DE MAIOR CONTRIBUIÇÃO PARA EPILEPTOGÊNESE...

PLOS ONE

RESEARCH ARTICLE

The Role of Hemosiderin Excision in Seizure Outcome in Cerebral Cavernous Malformation Surgery: A Systematic Review and Meta-Analysis

Di Ruan[®], Xiao-Bo Yu[®], Sudeep Shrestha, Lin Wang, Gao Chen*

Department of Neurosurgery, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, the People's Republic of China

These authors contributed equally to this work.

* d.chengao@163.com

Conclusion

Patients who underwent extended surrounding hemosiderin excision could exhibit significantly improved seizure outcomes compared to patients without hemosiderin excision However, further well-designed prospective multiple-center RCT studies are still needed.

Neurosurg Rev DOI 10.1007/s10143-016-0797-5

SHORT REVIEW

Should we resect peri-lesional hemosiderin deposits when performing lesionectomy in patients with cavernoma-related epilepsy (CRE)?


P. Dammann^{1,2} \cdot C. Schaller² \cdot U. Sure¹







INFLUÊNCIA DE PARÂMETROS PRÉ OPERATÓRIOS NAS EPILEPSIAS ASSOCIADAS À CCM





LOBECTOMIA TEMPORAL (1/3 OU 2/3 RESSECÇÃO)

LESIONECTOMIA AMIGADLO HIPOCAMPECTOMIA

Belie et al., Surgical management and long-term seizure outcome after epilepsy surgery for different types of epilepsy associated with cerebral cavernous malformations Epilepsia, 54(9):1699–1706, 2013

CAVERNOMA E EPILEPSIA (118)

There exists a preliminary recommendation by the Surgical Task Force of the ILAE Commission on Therapeutic Strategies to remove the hemosiderin deposits (Rosenow et al., ILAE, Epilepsia 54:2025-2035, 2013)


76 FÁRMACO RESISTENTE **20 EPILEPSIA CRÔNICA 22 CRISES ESPORÁDICAS**


LESIONECTOMIA

Ressecção depósito hemossiderina e adjacente córtex



Hemossiderna SEM ou **INCOMPLETA** ressecção









MAL FORMAÇÃO CAVERNOSA CEREBRAL

Prof. Jorge Marcondes de Souza, Docente permanente do PPGEURO



ALTOS NÍVEIS DE INF-GAMA E IL-18 EM PACIENTES COM MALFORMAÇÃO CAVERNOSA CEREBRAL (CCM) PODEM REPRESENTAR POSSÍVEIS BIOMARCADORES **PLASMÁTICOS DE EPILEPSIA**




Apresentação Clínica

Gonçalves J. P. C.¹²; Fontes-Dantas F. L.²; Dutra A.¹²; Alves-Leon S. V.²; Campolina D.³; Galvão G.¹; Domingues F.³; Leite P. E. C. L.⁴; Souza J. M.³

1 - Faculdade de Medicina - Universidade Federal do Rio de Janeiro. 2 - Laboratório de Neurociências Translacional – PPGNEURO – Universidade Federal do Estado do Rio de Janeiro. 3- Serviço de Neurocirurgia – Hospital Universitário Clementino Fraga Filho – Universidade Federal do Rio de Janeiro. 4 – Instituto Nacional de Metrologia, Qualidade e Tecnologia, INMETRO, Brasil.





Citocinas Plasmáticas

Gênero Feminino






LabNet está 🙂 se sentindo feliz em Windsor Barra.

27 de setembro às 22:43 · Rio de Janeiro · 🛞

Hoje durante IX Congresso da ABN-RJ/ANERJ tivemos prêmios em dose dupla para o LabNet. Ganhamos na categoria trabalho original apresentado pelo aluno de IC João Paulo, e na categoria caso clínico com a Pósdoutoranda Fabrícia Fontes. Os trabalhos premiados fazem parte da linha de pesquisa que estuda os mecanismos imunes e genéticos relacionados ao Cavernoma Cerebral em parceria com o professor Jorge Marcondes da UFRJ e Aliança Cavernoma do Brasil.






VARIANTS IN INFLAMMATION-RELATED GENES AND DNA REPAIR ENZYMES AFFECT SEVERITY IN A CCM3 BRAZILIAN PATIENT WITH CEREBRAL CAVERNOUS MALFORMATIONS


Fabricia Fontes-Dantas¹, Amanda Dutra ^{1,2}, Elielson Veloso ^{1,3}, Diego Campolina ⁴, Gustavo Galvão ², Larissa Watabe², Flavio Domingues⁴, Marcelo Chagas Muniz⁴, Soniza Alves-Leon^{1,5,} Jorge Marcondes de Souza^{1,4}.

Correspondence e-mail: jormarcondes@gmail.com





Dra. Fabrícia Lima Fontes-Dantas, MD, PhD Dra. Amanda Duta, MSC



IX CONGRESSO DA

ABN-RJ/ANERJ

Figure 2. Sequencing analysis: A) Coverage parameters and amplicons sequencing. B) Functional impact of identified variants.



Simpósio Internacional da Cavernoma Alliance, Professor Issan Awadi, Presidente da Cavernoma Alliance Sra. Conny Lee e pesquisadores do nosso LabNet/UNIRIO.



CONSIDERAÇÕES FINAIS

TAKE HOME MESSAGE

- EPILEPSIA é a manifestação mais frequente dos CCMs
- Epilepsia em Centro de Referência
- Pacientes com CRE recém diagnostic. frequência semelhante aos pacientes d
- EFR inclui a topografia e a associação Hipocampal/tumores (patologia dual/tr
- CRE apresenta múltiplos mecanismos de epileptogênese que vão além da

É recomendado definir a correlação dos CCMs e identificação neuroanatômica com

J Neurosurg. 2019 Jul 1;131(1):1-13. doi: 10.3171/2019.3.JNS181724. Cavernous angiomas: deconstructing a neurosurgical disease. Awad IA, Polster SP.

localização e podem incluir processos imunes/inflamatórios sugerindo novos alvos terapêuticos e a necessidade de avaliação de desfecho tendo como alvo a Epilepsia








HUCFF Hospital Universitário Clementino Fraga Filho





PROGRAMA DE PÓS GRADUAÇÃO EM NEUROLOGIA UNIVERSIDADE FEDERAL DO ESTADO DO RIO DE JANEIRO (UNIRIO)





Aliança Cavernoma Brasil @Aliancacavernomabrasil

IMPACTO NA EDUCACÃO MÉDICA **NO CONHECIMENTO DA DOENÇA**





CONHECIMENTO

PROFESSORA SELVA DE SOUZA PRESIDENTE DA AC BRASIL

PROFESSOR JORGE MARCONDES **PESQUISADOR COORDENADOR**





CAVERNOMA.ORG.BR